Interestingly, wtTRPM7 (M7-wt) increase the CD133 and ALDH1 expression in all glioma cell lines tested, however dead kinase domain of TRPM7 (M7-KR and M7-DK) downregulate the expression of CD133 and ALDH1 compared to controls (M7-wt), which indicates that disruption of kinase domain would reduce the TRPM7 activation resulting in reduced activation of stem cell markers CD133 and ALDH1. Here, TRPM7 is linked to glioma.